Cardiovascular Collaboration and Licensing Deals 2016-2026

Key Benefits

✔ Benchmark against 664 cardiovascular partnering deals – Access real-world collaboration and licensing activity to identify relevant precedents and comparable transactions.

✔ Benchmark cardiovascular deal financials – Analyze disclosed headline values, upfront payments, milestones and royalty rates and investigate the individual transactions behind the benchmarks.

✔ Identify prospective partners and leading dealmakers – Discover companies with demonstrated interest in cardiovascular assets, technologies, therapeutic indications and relevant stages of development.

✔ Compare activity across the cardiovascular landscape – Analyze dealmaking by therapeutic indication, development stage, technology type, deal type, industry sector and company.

✔ Find the most relevant comparable transactions – Move beyond broad averages to identify deals involving similar indications, technologies, development stages and partnering structures.

✔ Understand how cardiovascular deals are structured – Examine licensing rights, development responsibilities, exclusivity, IP, commercialization rights, milestones, royalties and other important transaction provisions.

✔ Learn from real contract documents – Where publicly available, review underlying agreements to understand how rights, obligations, financial terms and other negotiated provisions have been documented.

✔ Apply the intelligence to your own cardiovascular opportunity – Qualifying customers may also be eligible for a Customized Executive Partnering Briefing focused on their own asset, indication, technology, prospective partners or transaction objectives.

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in cardiovascular dealmaking

 

2.1. Introduction

2.2. Cardiovascular partnering over the years     

2.3. Cardiovascular partnering by deal type

2.4. Cardiovascular partnering by industry sector

2.5. Cardiovascular partnering by stage of development

2.6. Cardiovascular partnering by technology type

2.7. Cardiovascular partnering by therapeutic indication

 

Chapter 3 – Financial deal terms for cardiovascular partnering

 

3.1. Introduction

3.2. Disclosed financials terms for cardiovascular partnering

3.3. Cardiovascular partnering headline values

3.4. Cardiovascular deal upfront payments

3.5. Cardiovascular deal milestone payments

3.6. Cardiovascular royalty rates

 

Chapter 4 – Leading cardiovascular deals and dealmakers

 

4.1. Introduction

4.2. Most active in cardiovascular partnering

4.3. List of most active dealmakers in cardiovascular    

4.4. Top cardiovascular deals by value

 

Chapter 5 – Cardiovascular contract document directory

                                            

5.1. Introduction

5.2. Cardiovascular partnering deals where contract document available

 

Chapter 6 – Cardiovascular dealmaking by therapeutic target

 

6.1. Introduction

6.2. Deals by cardiovascular therapeutic target

 

Deal directory

 

Deal directory – Cardiovascular deals by company A-Z

Deal directory – Cardiovascular deals by technology type

 

Deal type definitions

 

About Biopharma Research Ltd

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Cardiovascular partnering since 2016

Figure 2: Cardiovascular partnering by deal type since 2016

Figure 3: Cardiovascular partnering by industry sector since 2016

Figure 4: Cardiovascular partnering by stage of development since 2016

Figure 5: Cardiovascular partnering by technology type since 2016

Figure 6: Cardiovascular partnering by indication since 2016

Figure 7: Cardiovascular deals with a headline value

Figure 8: Cardiovascular deals with upfront payment values

Figure 9: Cardiovascular deals with milestone payment

Figure 10: Cardiovascular deals with royalty rates

Figure 11: Active cardiovascular dealmaking activity since 2016

Figure 12: Top cardiovascular deals by value since 2016

Pricing options

• $3,995: single-user (encrypted file - one user/device)
• $5,995: multi-user (encrypted file - up to 5 users/devices)
• $7,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

3DR Labs, 4D Molecular Therapeutics, 4D Pharma, 23andMe, A*STAR Agency for Science, Technology and Research, Abbisko Therapeutics, Abbott Laboratories, Abbott Vascular Devices, Abbvie, Acandis, Acasti Pharma, Accenture, Access Scientific, AccuLine, AccurKardia, ACEA Biosciences, Actelion, Acutus Medical, ADAS 3D Medical, AddUp, Admera Health, Advanced BioInformatics, Advanced Catheter Therapies, Adventus Ventures, Aegerion Pharmaceutical, Aerolase, Affinia Therapeutics, AFFiRiS, AGC Biologics, Agepha Pharma, AgeX Therapeutics, Ahngook Pharmaceuticals, Aidoc, Akcea Therapeutics, Akebia Therapeutics, Albert Einstein College of Medicine, Aleris, Alexion Pharmaceuticals, Alibaba Health, AliveCor, ALK-Abello, Allelica, Allscripts, Alnylam Pharmaceuticals, Altamira Therapeutics, Amarin, Ambry Genetics, American College of Cardiology, American Heart Association, American Pharmaceutical Association, Amgen, AMO Pharma, Amryt Pharma, AnaBios, Analog Devices, AnaMar, Ancora Heart, Andelyn Biosciences, AnGes MG, Angiogenesis Foundation, Angion Biomedica, Angionetics, AngioSoma, Antares Pharma, Antaros Medical, Anthos Therapeutics, Anumana, Apicore, Aplagon, Apollo Therapeutics, Apotex, Apple, Aptahem, Aralez Pharmaceuticals, Ardelyx, Arena Pharmaceuticals, argenx, Argo Biopharma, Argon Medical Devices, Armatus Bio, Arrowhead Pharmaceuticals, Asahi Kasei, Ascendis Pharma, Aspire Health Science, Astellas Pharma, AstraZeneca, AtCor Medical, Atelerix, Athena Bioscience, Athersys, Attune Medical, Audentes Therapeutics, Australian Research Council, Autotelic BIO, Avania, Avery Therapeutics, Avicenna Technology, Avidity Biosciences, Avinger, Avrobio, Axiogenesis, Axol Bioscience, Aziyo Biologics, Azurity Pharmaceuticals, B-Secur, Babraham Institute, Bausch Health Companies, Baxter International, Bayer, Bay Labs, Baylor College, Beam Therapeutics, Beijing SL Pharma, Bened Biomedical, BenevolentAI, Beth Israel Deaconess Medical Center, Bicycle Therapeutics, BioCardia, Biocon, Biofourmis, BioIntelliSense, BioLamina, BIOLIFE4D, BioMarin Pharmaceutical, BioMatrix Specialty Pharmacy, Biomerics, BioPep, BioSig Technologies, Biotheus, Biotricity, Biotronik, BioVectra, Bioventix, Biovic Sdn bhd, Bird Foundation, Bitterroot Bio, BiVACOR, BlueRock Therapeutics, Blue Water Biotech, Boehringer Ingelheim, Boston Medical Center, Boston Pharmaceuticals, Boston Scientific, Braveheart Bio, BridgeBio Pharma, Brigham and Women's Hospital, Brigham Young University, BrightInsight, Bristol-Myers Squibb, Broad Institute, Broncus Technologies, Brooks Automation, Butterfly Network, Cadila Pharmaceuticals, Caerus Strength, Caladrius Biosciences, California Institute of Technology, Canadian Institutes of Health Research, Cap Alter Pharma, Capricor Therapeutics, Capsule Tech, CardiaCare, Cardiac Insight, Cardialen, CardieX, CardiNor, CardioFocus, Cardiogen Sciences, Cardiomatics, Cardiome Pharma, Cardiovascular Research Foundation, Cardiovascular Solutions of Central Mississippi, Cardiovascular Systems, Cardiowise, Cardurion Pharmaceuticals, Carestream Health, CareTaker Medical, Caristo Diagnostics, Carmat, Carmel Pharma, Carrum Health, Case Western Reserve University, Catalent, Catheter Precision, CB Scientific, Ceapro, Cedars-Sinai Medical Center, Celanese, Cell and Gene Therapy Catapult, CELLINK, Cellino Biotech, CellProThera, Cell Therapy, Celltrion, Centers for Disease Control and Prevention, Cevec Pharmaceuticals, Chang Gung University, Chansu Vascular Technologies, Charles River Laboratories, Cheil Pharm, Chemify, Children's Heart Foundation, Children's Hospital Boston, Children's Hospital of Philadelphia, Children's Medical Research Institute, China Grand Pharmaceutical, China Resources Sanjiu Medical and Pharmaceutical, Chinese Society of Cardiology, Cholesgen, CinCor Pharma, Cipherome, Cipla, Circle cardiovascular imaging, Citius Pharmaceuticals, Civica Rx, Clario, Cleveland Clinic, Clinical Consultants International, Closed Loop Medicine, Coala Life, Columbia University Medical Center, CoreRx Pharma, Corindus Vascular Robotics, Cornell University, Correvio Pharma, Corvidia Therapeutics, CORXEL Pharmaceuticals, Cosette Pharmaceuticals, Covalon Technologies, Creative Medical Technologies, CRISPR Therapeutics, Critical Diagnostics, Crown Bioscience, CSL, CSPC Pharmaceutical Group, Curadev Pharma, Curi Bio, CVie, CyberHeart, Cyclenium Pharma, Cyclerion Therapeutics, Cytokinetics, Daiichi Sankyo, Dalhousie University, Dassault Systems, Datos Health, DaVinci Biomedical Research Products, deCODE Genetics, Deep Apple Therapeutics, Denovium, Denovo Biopharma, Department of Defense, Dewpoint Therapeutics, DHR Health, Diablo Clinical Research, DiA Imaging Analysis, Dicerna Pharmaceuticals, DiNAQOR, DKSH, DNAnexus, Dogma Therapeutics, Dorizoe Lifesciences, Dr. Reddy's Laboratories, Duke-NUS Graduate Medical School Singapore, Duke Clinical Research Institute (DCRI), Duke University, Duke University Medical Center, Dyno Therapeutics, Eccogene, EchoNous, Edwards Lifesciences, eGenesis, Egnite, Eidos Therapeutics, Eko, Eko Health, ELC Group, Eledon Pharmaceuticals, Eleven Biotherapeutics, Elexopharm, Eligo Bioscience, Eli Lilly, Embolx, Emory University, Enamine, Enogenesis, Enzolytics, Epsilon, Er-Kim, Erasmus University Medical Center, ERS Genomics, Esperion Therapeutics, Espero Biopharma, Essential Pharma, Ethris, Etiometry, Eureka Eurostars, European Innovation Council, European Wellness Biomedical Group, Everest Medicines, Evotec, Evox Therapeutics, Exo, Exscientia, Feinstein Institute for Medical Research, FEops, FibriCheck, Fine Foods & Pharmaceuticals N.T.M., FitBit, Flagship Biosciences, Flagship Pioneering, Food and Drug Administration (FDA), Forcefield Therapeutics, Foresee Pharmaceuticals, Forge Biologics, Fortress Biotech, Freeline Therapeutics, Frontier Biotech, Fujifilm, Fujifilm medical systems, Fuji Yakuhin, Fulcrum Therapeutics, G3 Pharmaceuticals, G3 Therapeutics, Gatehouse Bio, GC Pharma, GE Healthcare, Geisinger Medical Center, Gemphire, GenEditBio, Genevant Sciences, Genome Biologics, Genomic Vision, Gensaic, George Clinical, George Medicines, Georgetown University, Georgia Institute of Technology, German Ministry for Education and Research, Gestion Univalor, Getinge, Gibraltar Health Authority, Global Genomics Group, GNS Healthcare, Gossamer Bio, Government of South Korea, Grunenthal, GS, Guangdong Provincial People's Hospital, Hainan Sihuan Pharmaceutical, Hancock Jaffe Laboratories, Handok Pharmaceuticals, Harvard Pilgrim Health Care, Harvard Stem Cell Institute, Harvard University, Hasten Biopharmaceutic, HAYA Therapeutics, HCM Registry, Healios K.K., Healium Medical, Health Recovery Solutions, Health Sciences Research Institute Germans Trias i Pujol Foundation, HeartBeam, Heartflow, HeartHero, Heart Rhythm Clinical Research Solutions, HeartSciences, Heartseed, Helix, HELP Therapeutics, Hemostemix, Henry Ford Health System, Heqet Therapeutics, Hetero Labs, High Desert Heart Institute, HighLife, Hikma Pharmaceuticals, HitGen, HLS Therapeutics, Holberg EEG, HoliStick Medical, Hologic, Horizon Discovery, Horizon Europe, Hospital for Sick Children, Huadong Medicine, Huami, Huapont Pharma, Humacyte, Human Biosystems, Hyloris Pharmaceuticals, Icahn School of Medicine at Mount Sinai, iCardiac Technologies, Idorsia, iECURE, ii Ventures, Illumina, ImagineMIC, IME Medical Electrospinning, ImpediMed, Imperial College London, Imricor Medical Systems, InCarda Therapeutics, Indiana University, InfoBionic.Ai, inHealth Medical, inHEART, Innosuisse, Innovate UK, Innovation Network Corporation, Innova Vascular, Innovent Biologics, InQB8 Medical Technologies, Insilico Biotechnology, Insilico Medicine, Inspyr Therapeutics, Institute of Human Virology, Integrated DNA Technologies, Intermountain Healthcare, International Society of Heart and Lung Transplantation, Ionis Pharmaceuticals, I Peace, IQVIA, iRhythm Technology, Istituti Clinici Scientifici Maugeria, Itochu, Ixaka, Jackson Laboratory, Jacksonville Pharmaceuticals, Jana Care, JanOne, Janssen Pharmaceuticals, Janssen Research & Development, Jarvik Heart, JenaValve Technology, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, Ji Xing Pharmaceuticals, Johns Hopkins Medicine (JHM), Johns Hopkins University, Johnson & Johnson, Juntendo University, Kahn-Sagol-Maccabi, Kalos Medical, Kantonsspital St. Gallen, Karis Bio, Kastle Therapeutics, Keystone Heart, Kiniksa Pharmaceuticals, Kiromic Biopharma, Kissei Pharmaceutical, Kitov Pharma, Korro Bio, Kowa, Kuhnil Pharmaceuticals, Kyoto University, Kyowa Hakko Kirin, Kyttaro, Laboratory Corporation of America, La Jolla Capital, La Jolla Pharmaceutical, Lannett, Lantheus Medical Imaging, Laurel Bridge Software, Lee's Pharmaceutical, Leiden University, Leonhardt's Launchpads, LEO Pharma, Leviticus Cardio, LEXEO Therapeutics, Lexicon Pharmaceuticals, Lexington Biosciences, LianBio, LIB Therapeutics, LifeQ, LifeStrands Genomics, LifeTech Scientific, LifeWatch Services, Ligand Pharmaceuticals, LindaCare, Lipigon Pharmaceuticals, Longeveron, Lonza, Lotus Pharmaceuticals, LSU Health Sciences Center, LUCA Science, Lund University, Luscii, mAbsolve, Magnesium Elektron, Mallinckrodt Pharmaceuticals, Marizyme, Marpai, Massachusetts General Hospital, Massachusetts Institute of Technology, Max Biopharma, Mayo Clinic, McGill University, MD Anderson Cancer Center, MDF Instruments, Medable, MedAxiom, MedCision, Medicardia Health, MediciNova, Medicure, MedImmune, Medipal Holdings, MediSafe, Medis Medical Imaging, Mediso, Medison Pharma, Meditrial Europe, Medtronic, Melinta Therapeutics, Menarini, Mentice, Merck and Co, Merck KGaA, Mesoblast, Mespere LifeSciences, Metaba, MetaSight Diagnostics, Metrion Biosciences, Micro Interventional Devices, Milestone Pharmaceuticals, Minnetronix, Mobvoi, Mochida Pharmaceutical, Moderna, Molecular Stethoscope, Monash University, Montefiore Health System, Montreal Heart Institute, Mperia Therapeutics, Mpirik, Munich Reinsurance Company, Myant, Myocarditis Foundation, MyoKardia, Myriad RBM, N8 Medical, Nagoya University Graduate School of Medicine, NAMSA, Nano-X Imaging, NanoSurface Biomedical, NanoVation Therapeutics, NASA, Nashville Biosciences, National Cancer Center, National Cancer Institute, National Center for Cardiovascular Diseases, National Cerebral and Cardiovascular Disease Research Center, National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute on Aging, National Institutes of Health, National Organization for Rare Disorders, National Physical Laboratory, National University of Ireland, Galway (NUI Galway), Nationwide Children’s Hospital, Natus Medical, Ncardia, NeoChord, Neomorph, Neovasc, Neurimmune Therapeutics, NeuroproteXeon, New American Therapeutics, NewAmsterdam Pharma, New Wave Ventures, New York Institute of Technology, New York University, NGM Biopharmaceuticals, NHS Scotland, Nightingale Health, NIMIUM Therapeutics, Ninety One, Nissan Chemical Industries, North Carolina State University, Northwestern Medicine Bluhm Cardiovascular Institute, Northwestern University, NovalGen, Novartis, Novocardia, Novoheart, Novo Integrated Sciences, Novo Nordisk, Novostia, NTT Data, NTT Medical Center Tokyo, Numares, Numerate, NuvoAir, Nxera Pharma, Octapharma, Ohio State University, OliX Pharmaceuticals, OMEICOS Therapeutics, Omron, OncoImmune, One Drop, OnFace, Opsens, OptiBiotix, Optina Diagnostics, Opus Medical, Orchestra BioMed, Orebro University, Organicell Regenerative Medicine, Orient EuroPharma, ORIG3N, Oscor, OSE Immunotherapeutics, Otsuka, Ovation, Owkin, Owlstone Medical, PaceMate, Paion, Paragonix Technologies, Paraza Pharma, Paul G Allen Family Foundation, Peijia Medical, Peking University, Penn Medicine, PeptiDream, Pfizer, PharmAbcine, Pharmabiota, Pharmanovia, Pharma Scientific Research, Pharmazz, Pharnext, PhaseBio Pharmaceuticals, Phibro Animal Health, Philips, Phlox Therapeutics, PhoreMost, Photys Therapeutics, PhysIQ, Pierre Fabre, Pilloxa, PlaqueTec, Pluriomics, Pluristem Therapeutics, Pohl Boskamp, Population Health Research Institute, Precision BioSciences, Precision Image Analysis, Premier Inc, Prevail InfoWorks, Prevencio, Primary Peptides, Primevera Therapeutics, Primordial Genetics, Procella Therapeutics, Profil Institute for Clinical Research, ProFound Therapeutics, Profusa, Project HOPE, ProtoKinetix, PulseCath, Punjab Province, Qilu Pharmaceutical, Qingdao Primedicine Pharmaceutical, Qualigen, Quercis Pharma, Quest Diagnostics, Quotient Therapeutics, Rain Oncology, Rancho Santa Fe Bio, Recordati, ReCor Medical, Redoxis, Redwire, Reemo Health, ReFlow Medical, Regenerative Care Network, Regenerative Medicine of Latin America, Regeneron Pharmaceuticals, Regenxbio, Regio Biosciences, Rejuvenate Bio, Relaxera Pharmazeutische, Reliance Life Sciences, Renova Therapeutics, Repair Biotechnologies, Replicate Bioscience, Research Development Foundation, Respira Therapeutics, Resverlogix, Retia Medical, Revive Therapeutics, Rexgenero, Rex Medical, Rigel Pharmaceuticals, Riparian Pharmaceuticals, Roche, Roche Diagnostics, Rocket Pharmaceuticals, Roivant Sciences, RoosterBio, Royal Philips Electronics, RTW Investments, Rutgers University, SACCO, Salipro Biotech, Samsung Biologics, Samsung Electronics, Sanacor, Sana Klinikum Offenbach, SandboxAQ, Sandoz, SanegeneBio, Sanofi, Sarepta Therapeutics, Sarfez Pharmaceuticals, SCIMAGE, ScinoPharm Taiwan, Scipher Medicine, Sciwind Biosciences, Scohia Pharma, scPharmaceuticals, Seattle Childrens Research Institute, Secant Medical, Secarna Pharmaceuticals, Sema4, Semmelweis University, Sensifree, Senti Biosciences, Septerna, Seqirus, SERB Pharmaceuticals, SFJ Pharmaceuticals, Shanghai Argo Biopharmaceutical, Shanghai Model Organisms Center, Shenzhen Salubris Pharmaceuticals, Shenzhen Semacare Medical Technology, Shimadzu, Shire Pharmaceuticals, Siemens Healthineers, SignPath Pharmaceuticals, Silence Therapeutics, Sinomed, Sirius Therapeutics, Sirtex Medical, SkylineDX, Skyline Therapeutics, SmartCella, Smartwise, SNBL CPC, Societal CDMO, Society of NeuroInterventional Surgery, Society of Vascular and Interventional Neurology, Solid Biosciences, SomaLogic, SonoScape Medical, SOPHiA Genetics, Sosei, Sosei Heptares, Soufflé Therapeutics, Soundbite Medical, Southwest Research Institute, Southwest Transplant Alliance, Spacelabs Healthcare, Sphingotec, SQI Diagnostics, SQ Innovation, Standard BioTools, Stanford University, Stanford University School of Medicine, Staten Biotechnology, Stealth BioTherapeutics, StemCardia, Stempeutics, STENTiT, Stereotaxis, StrideBio, Sumocor, Sunshine Lake Pharma, Surge Cardiovascular, SurModics, Suzhou Ribo Life Sciences, Swedish Bactiguard, SymphonyAI, SynAct Pharma, Syneos Health, SynerK, Syntach, Syntactx, Takeda Pharmaceutical, Talis Biomedical, TARA Biosystems, Taros Chemicals, Tasly Pharmaceuticals, Teleflex, Tempus, Tenaya Therapeutics, Terason, Terumo, Terumo Aortic, Terumo Cardiovascular Systems, Teson Pharma, Texas Instruments, TGen Drug Development, The Foundry, TheraVasc, Thermo Fisher Scientific, The University of Chicago Medicine, Third Pole Therapeutics, Toolgen, Topstone Research, Toray, toSense, Transgenomic, TriHealth, Triple Ring Technologies, Tris Pharma, TTP Group, twoXAR, UAB Research Foundation, Ubiquigent, Ultragenyx Pharmaceuticals, UltraSight, Ultromics, Unilife, UniQure, United Imaging Healthcare, United Therapeutics, University College London, University of Alabama, University of Bern, University of British Columbia, University of California, San Diego, University of California San Francisco, University of Cambridge, University of Cincinnati, University of Colorado, University of Erlangen, University of Glasgow, University of Iowa, University of Lausanne, University of Manchester, University of Maryland, University of Miami, University of Nebraska, University of Oslo, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of the Highlands and Islands, University of Utah Research Foundation, University of Washington, University of West Indies, University of Wisconsin-Madison, Unnatural Products, Us2.ai, Valo Health, Vanderbilt University, Variant Bio, Vascugen, Vascular Flow Technologies, Vasomune Therapeutics, Vastrax, VectraCor, Venturis Therapeutics, Venus Medtech, Verantos, Verdiva Bio, Verily, Verizon, Verve Therapeutics, VFLO Medical, Viatris, Vifor Pharma, Vince & Associates Clinical Research, Vincere Biosciences, Visirna Therapeutics, Vitro Biopharma, Viva Biotech, VivaQuant, Vivasc Therapeutics, VivoSense, Viz.ai, Vizient, VolitionRX, Volta Medical, VOTIS Subdermal Imaging Technologies, Voyager Therapeutics, Wacker Biotech, Wake Forest University, WakeMed Health & Hospitals, Wallace H. Coulter Foundation, Washington University in St Louis, Weill Cornell Medical College, WellDoc, Western New England University, West Pharmaceutical Services, Windtree Therapeutics, Winthrop-University Hospital, World Heart Federation, WraSer Pharmaceuticals, Xentria, Xspire Pharma, XyloCor Therapeutics, Yale School of Medicine, Yale University, YolTech Therapeutics, ZAO Firma Euroservice, ZeClinics, Zelira Therapeutics, Zhittya Genesis Medicine, Zoll Medical, Zora Biosciences, Zylox Tonbridge Medical Technology Co, Ltd

About Current Partnering

A definitive, evidence-based approach to dealmaking intelligence

Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.

Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.

All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.

---

Our methodology

Built on a continuously updated proprietary database

All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.

Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.

---

Comprehensive and verifiable data sourcing

Deal data is sourced from publicly available industry disclosures, including:

• Company press releases and announcements
• SEC filings and equivalent regulatory disclosures
• Company and investor presentations
• Conference materials and company websites

All sources are captured and referenced, enabling full transparency and user verification.

---

Broad coverage across deal types and structures

Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:

• Licensing and co-development
• Research and collaborative R&D
• Manufacturing, supply, and distribution
• Commercialisation and co-promotion
• Equity investments, joint ventures, and asset transactions
• Options, royalties, and financing agreements

This breadth ensures a complete view of how partnerships are structured across the life sciences sector.

---

Structured, standardised analysis

Every deal is analysed using a consistent framework, capturing (where disclosed):

• Financial terms — including upfront payments, milestones, and royalties
• Rights allocation — development, manufacturing, and commercialization responsibilities
• Deal structure — exclusivity, territorial scope, and agreement type
• Contractual provisions — clauses defining risk, control, and value-sharing

Each deal record is fully categorised, including data fields such as:

• Therapy area and technology type
• Stage of development
• Asset type and deal components
• Geographic scope and exclusivity
• Source documentation, including press releases and SEC filings

---

Financial normalisation for comparability

All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.

---

Contract-level insight

Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.

This enables users to understand:

• How financial mechanisms are defined and triggered
• How responsibilities are operationalised between parties
• How flexibility, risk, and control are allocated within agreements

---

Designed for real-world application

Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including:

• Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy
• Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour
• Advisory, legal, and consulting firms — supporting client engagements with real-world precedent and contract-level insight

Common use cases include:

• Benchmarking comparable transactions
• Supporting valuation and deal structuring
• Preparing for negotiations
• Evaluating potential partners
• Informing internal strategy with real-world evidence

---

A trusted industry reference

With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies, emerging biotechs, investors, and advisory firms as a trusted source of dealmaking intelligence.

By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.